



ADVANCED STERILIZATION PRODUCTS®

a *Johnson & Johnson* company

Division of Ethicon, Inc.

March 17, 2009

Novartis Pharma AG
Fabrikstrasse 12-4.03A.10
CH-4002 Basel
Switzerland

Attention: [REDACTED]

Ladies and Gentlemen:

This Letter Agreement (the "Agreement") will confirm recent discussions between Advanced Sterilization Product division of Ethicon, Inc. ("ASP") located at 29B Technology Drive, Irvine, CA 92618, USA and Novartis Pharma AG ("Novartis") located at Forum 1, Novartis Campus, 4056 Basel, Switzerland regarding an interest in evaluating certain of each other's business and technical information for the purpose of determining whether certain Novartis products are compatible with ASP's STERRAD® sterilization systems. In this regard, ASP wishes to evaluate certain information and data relating solely to Novartis' Lucentis® product (the "Product"), which Novartis considers to be confidential and proprietary. Novartis wishes to evaluate certain information and data relating to ASP's STERRAD® GMP sterilization systems (the "Systems"), which ASP considers to be confidential and proprietary. Each party agrees to disclose to and receive from the other, or allow the other to have access to, such party's confidential and proprietary information, only upon the following terms and conditions:

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

Very truly yours,

Advanced Sterilization Product
division of Ethicon, Inc.

[REDACTED]

APPROVED AND ACCEPTED THIS _____ DAY OF _____, 2009.

Novartis Pharma AG

By: _____

Title: _____

By: _____

Title: _____